Track market-moving stories before they get noisy

HomeStock IdeasLong IdeasHealthcare 

SummaryCrispr Therapeutics secured FDA pediatric approval for Casgevy, expanding its addressable market and reinforcing its leadership in CRISPR/Cas9 gene editing.Casgevy’s robust clinical efficacy, global approvals, and strong safety profile support its multibillion-dollar potential, despite initial slow commercial uptake due to complex treatment and high cost.CRSP’s pipeline includes innovative in-vivo and allogeneic programs targeting cardiovascular and autoimmune diseases, aiming to further simplify and expand gene therapy applications.With pediatric approval, CRSP is positioned for accelerated revenue growth; patient pool expansion and technical advances could drive significant upside toward historic share price highs.Haggerston BioHealth members get exclusive access to our real-world portfolio. See all our investments here » wildpixel/iStock via Getty Images

Investment Overview - Casgevy Secures Pediatric Approval Crispr Therapeutics (CRSP) stock jumped >8% in trading yesterday, reaching a four-month high value of $60 per share and a market cap valuation of $5.79bn, after the company and partner Vertex Pharmaceuticals (

15.01K Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of CRSP either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.